Olema Pharmaceuticals, Inc. $OLMA Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 16.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 618,184 shares of the company’s stock after buying an additional 85,073 shares during the quarter. Schroder Investment Management Group owned about 0.90% of Olema Pharmaceuticals worth $2,633,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Ameritas Investment Partners Inc. boosted its holdings in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after purchasing an additional 5,866 shares during the period. FNY Investment Advisers LLC lifted its position in shares of Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 5,000 shares in the last quarter. Quarry LP purchased a new position in shares of Olema Pharmaceuticals in the first quarter valued at $45,000. Finally, Alpine Global Management LLC acquired a new stake in Olema Pharmaceuticals during the 1st quarter valued at $52,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on OLMA. Guggenheim started coverage on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price objective on the stock. UBS Group reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. The Goldman Sachs Group increased their price target on Olema Pharmaceuticals from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 21st. Citigroup raised their price objective on Olema Pharmaceuticals from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Insider Activity

In related news, Director Cyrus Harmon sold 3,086 shares of the firm’s stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $8.32, for a total transaction of $25,675.52. Following the transaction, the director directly owned 117,028 shares in the company, valued at $973,672.96. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 25,000 shares of company stock worth $204,841. Corporate insiders own 16.36% of the company’s stock.

Olema Pharmaceuticals Stock Down 1.6%

NASDAQ:OLMA opened at $27.21 on Friday. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -14.55 and a beta of 1.87. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $29.51. The stock has a 50-day simple moving average of $13.79 and a 200 day simple moving average of $8.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.